Shanghai, China

Bei Yuan


 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):

Title: Innovations of Inventor Bei Yuan

Introduction

Bei Yuan is a notable inventor based in Shanghai, China, recognized for his contributions to the field of pharmaceuticals. With a focus on medical applications, he has made significant strides in developing innovative solutions for health-related challenges. His work, particularly in antibody technology, showcases the intersection of science and medical treatment.

Latest Patents

Among his achievements, Bei Yuan holds a patent for a PCSK9 antibody, which includes an antigen-binding fragment and its medicinal applications. The invention provides a chimeric antibody and a humanized antibody, both incorporating a complementary-determining region (CDR) of the PCSK9 antibody. This patent is crucial as it encompasses a pharmaceutical composition that utilizes the PCSK9 antibody as a lipid-lowering agent. Specifically, the patent outlines the humanized PCSK9 antibody's application in creating pharmaceutical drugs intended to treat diseases associated with PCSK9.

Career Highlights

Throughout his career, Bei Yuan has been affiliated with prominent companies such as Jiangsu Hengrui Medicine Company Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. His experience in these organizations has undoubtedly enhanced his expertise and ability to innovate in the pharmaceutical field. These roles have allowed him to work on groundbreaking research and development projects, propelling him to the forefront of medical invention.

Collaborations

In his professional journey, Bei Yuan has collaborated with other talented individuals, including Xiangdong Qu and Xin Ye. These partnerships highlight the importance of teamwork in the realm of innovation, where diverse expertise and perspectives converge to create advanced solutions in healthcare.

Conclusion

In summary, Bei Yuan stands as a distinguished inventor, specifically in the domain of antibody development. His patent on the PCSK9 antibody marks a significant contribution to pharmaceutical innovations. As healthcare technology continues to evolve, the implications of his work promise to enhance treatment options for patients suffering from PCSK9-induced conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…